PPT-In silico virtual screening of known drugs against SARS-CoV-2 3CL protease:

A drug repurposing approach for COVID19 Md Riad Chowdhury 1 Md Adnan 2 Md Nazim Uddin Chy 1 ATM Mostafa Kamal 1 1 Department of Pharmacy International Islamic University Chittagong . The 100X Protease Inhibitor Cocktail is a clear colorless liquid Background In order to study speci64257c target proteins of interest proteasemediated degradation during the genera tion of protein lysates is to be avoided A loss of normal cellular c Bombyx mori. Present by . Mr.M.Kannan, M.Sc., PGDEG,. Research Scholar . Under the guidance of . Prof. . M.Krishnan . Insect Molecular Biology laboratory. Department of Environmental Biotechnology. Bharathidasan University, Tiruchirappalli-620 024. Bombyx mori. Present by . Mr.M.Kannan, M.Sc., PGDEG,. Research Scholar . Under the guidance of . Prof. . M.Krishnan . Insect Molecular Biology laboratory. Department of Environmental Biotechnology. Bharathidasan University, Tiruchirappalli-620 024.  . 4. th. Example of Human Specific Disease:.  . Coronaviruses.  . Classification.  . morphology and structure..  . Laboratory diagnosis..  . Treatment and Prevention. What are Coronaviruses?. January 272021Page 1d forStandarFinal 220 -16VAC25Infectious Disease Preventionofthe SARS-CoV-2 Virus That Causes COVID-19As Adopted by theSafety and Health Codes Boardon January 13 2021VIRGINIA OCCU One Health Partners Monthly COVID-19 WebinarCoordinated by the CDCOne Health Office in partnership with the One Health Federal Interagency COVID-19 Coordination OH-FICC GroupOne Emergx000Bg x000Crx000Ex000Fes Ix000Bfetx000Ex000BsISSN Prx000Btx001A x001Bx001Bx001Bx001B-x001Cx001Dx001Ex001C x000Blx000Bex001A Jx000Eurx000Bal hx000Emepage https//wwwtax000Bdfx000Ex000Blx000Bex000 The more the virus circulates, the more the virus will evolve
Most changes have little to no impact on the virus’s properties or behaviour
However, some changes to SARS-CoV-2 lead to the emergence of variants that may affect: May 27. 2020. K.Dharmalingam. Asymptomatic Likely but remote. Prodromal Yes. Oligosymptomatic Yes. Polysymptomatic Yes. Spread occurs from all these groups of patients. Fauci. , for one, still believes it does.. Analytical & Clinical Performance Data (OUS). June 2020. HOOD05162003091712. FTD SARS-CoV-2 Assay*. Instructions for Use. *. CE-IVD labelled for diagnostic use in the EU. . The . Instructions for Use . 1,2,3. *. , . Sarah Temmam. 4. *,. . Christèle. Huon. 4. , Sylvie Behillil. 5,6. , Vincent Gajdos. 7,8, . Thomas Bigo. t4,9. , Thibaut Lurier. 10,11,12. , Delphine Chrétien. 4. , . Marija. Backovic. Department Medicine. UF College of Medicine. Randomized trial of bicalutamide to block . TMPRSS2 in males with COVID-19 infection. UF-CTSI Pilot grant project. Association between . Cancer and COVID-19 Biology. Kratzel A, Todt D, V’kovski P, Steiner S, Gultom M, Thao T, et al. Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 by WHO-Recommended Hand Rub Formulations and Alcohols. Emerg Infect Dis. 2020;26(7):1592-1595. https://doi.org/10.3201/eid2607.200915. Also Called . 3CL Proteinase. Collaborative Curriculum Development Program 2020. What does SARS-CoV-2 look like? . Severe acute Respiratory Syndrome -Coronavirus-2. Large (~30Kb) . +RNA genome. . https://viralzone.expasy.org/764?outline=all_by_species.